5-Methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)
are two
of the most abundant epigenetic marks in mammalian genomes, and it
has been proven that these dual epigenetic marks give a more accurate
prediction of recurrence and survival in cancer than the individual
mark. However, due to the similar structure and low expression of
5mC and 5hmC, it is challenging to distinguish and quantify the two
methylation modifications. Herein, we employed the ten-eleven translocation
family dioxygenases (TET) to convert 5mC to 5hmC via a specific labeling process, which realized the identification of
the two marks based on a nanoconfined electrochemiluminescence (ECL)
platform combined with the amplification strategy of a recombinase
polymerase amplification (RPA)-assisted CRISPR/Cas13a system. Benefiting
from the TET-mediated conversion strategy, a highly consistent labeling
pathway was developed for identifying dual epigenetic marks on random
sequence, which reduced the system error effectively. The ECL platform
was established via preparing a carbonized polymer
dot embedded SiO2 nanonetwork (CPDs@SiO2), which
exhibited higher ECL efficiencies and more stable ECL performance
compared to those of the scattered emitters due to the nanoconfinement-enhanced
ECL effect. The proposed bioanalysis strategy could be employed for
the identification and quantification of 5mC and 5hmC in the range
from 100 aM to 100 pM, respectively, which provides a promising tool
for early diagnosis of diseases associated with abnormal methylation.